Literature DB >> 9851573

Subtypes of social phobia and comorbidity with depression and other anxiety disorders.

M B Stein1, D A Chavira.   

Abstract

Epidemiological studies have identified two subtypes of social phobia: speaking-only social phobia which is characterized by the fear of public speaking situations and complex social phobia which is characterized by the fear of multiple social situations. Speaking-only social phobia most closely corresponds to the DSM-IV's 'nongeneralized social phobia' while complex social phobia resembles 'generalized social phobia'. In contrast to the speaking-only social phobia, the complex form is usually more disabling, familial and longer-lasting. In addition, the complex form has a lower chance of spontaneous recovery and carries a higher risk of comorbidity and impairment. Overall, both types of social phobia tend to be underdiagnosed and under-treated. Effective treatments which can manage not only complex social phobia, but also its spectrum of comorbid conditions, are required.

Entities:  

Mesh:

Year:  1998        PMID: 9851573     DOI: 10.1016/s0165-0327(98)00092-5

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  10 in total

Review 1.  Unmasking social anxiety disorder.

Authors:  M B Stein; J M Gorman
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

Review 2.  Familial risk factors in social anxiety disorder: calling for a family-oriented approach for targeted prevention and early intervention.

Authors:  Susanne Knappe; Katja Beesdo-Baum; Hans-Ulrich Wittchen
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-10-06       Impact factor: 4.785

3.  Becoming the center of attention in social anxiety disorder: startle reactivity to a virtual audience during speech anticipation.

Authors:  Brian R Cornwell; Randi Heller; Arter Biggs; Daniel S Pine; Christian Grillon
Journal:  J Clin Psychiatry       Date:  2010-10-05       Impact factor: 4.384

Review 4.  Social anxiety disorder: recent findings in the areas of epidemiology, etiology, and treatment.

Authors:  C Blanco; K Nissenson; M R Liebowitz
Journal:  Curr Psychiatry Rep       Date:  2001-08       Impact factor: 5.285

5.  Social phobia and subtypes in the national comorbidity survey-adolescent supplement: prevalence, correlates, and comorbidity.

Authors:  Marcy Burstein; Jian-Ping He; Gabriela Kattan; Anne Marie Albano; Shelli Avenevoli; Kathleen R Merikangas
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-07-23       Impact factor: 8.829

6.  Emotion Regulation and the Transdiagnostic Role of Repetitive Negative Thinking in Adolescents with Social Anxiety and Depression.

Authors:  David H Klemanski; Joshua Curtiss; Katie A McLaughlin; Susan Nolen-Hoeksema
Journal:  Cognit Ther Res       Date:  2016-10-25

7.  Change in quality of life and their predictors in the long-term follow-up after group cognitive behavioral therapy for social anxiety disorder: a prospective cohort study.

Authors:  Norio Watanabe; Toshi A Furukawa; Junwen Chen; Yoshihiro Kinoshita; Yumi Nakano; Sei Ogawa; Tadashi Funayama; Tetsuji Ietsugu; Yumiko Noda
Journal:  BMC Psychiatry       Date:  2010-10-14       Impact factor: 3.630

8.  Social anxiety disorder in genuine halitosis patients.

Authors:  Takashi Zaitsu; Masayuki Ueno; Kayoko Shinada; Fredrick A Wright; Yoko Kawaguchi
Journal:  Health Qual Life Outcomes       Date:  2011-11-03       Impact factor: 3.186

9.  Differences in mGluR5 Availability Depending on the Level of Social Avoidance in Drug-Naïve Young Patients with Major Depressive Disorder.

Authors:  Jeong-Hee Kim; Yo-Han Joo; Young-Don Son; Hang-Keun Kim; Jong-Hoon Kim
Journal:  Neuropsychiatr Dis Treat       Date:  2022-09-12       Impact factor: 2.989

10.  Early Improvement in One Week Predicts the Treatment Response to Escitalopram in Patients with Social Anxiety Disorder: A Preliminary Study.

Authors:  Kang-Seob Oh; Eunsook Shin; Juwon Ha; Dongwon Shin; Youngchul Shin; Se-Won Lim
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-05-31       Impact factor: 2.582

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.